PitchSend

Nuvectis Pharma Investor Presentation Deck

Nuvectis Pharma - Key Highlights Our Approach to Precision Medicine NXP800 - Phase 1b NXP900 - IND accepted Management Team with Strong Track Record Select and acquire novel, rationally-designed drug candidates → Focus on drug development for serious conditions of unmet need in oncology Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma Phase 1b study initiated in collaboration with ENGOT/GOG Phase 1a expected to begin 3Q2023 First potential indications: YES1/SRC-driven solid tumors 3 approved drugs in 4 indications in the US and EU and multiple strategic deals Cash runway into 1H2025 Stock added to the Russell 2000 index in June 2023 3

View entire presentation